Company / Profit Margin
Corcept Therapeutics Incorporated Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
13.1%
FY2025
5-year range
13.1% / 30.7%
FY2021-FY2025
Trend
-37.4%
vs FY2024
Sector context
#35 of 145
Health Care
What the data says
Corcept Therapeutics Incorporated's profit margin of 13.1% is higher than 76% of companies in the Health Care sector (FY2025). Profit Margin has declined for 4 consecutive years, from 30.7% in FY2021 to 13.1% in FY2025.
Based on SEC 10-K filings.
13.1% in FY2025 with a 5-year CAGR of -16.9%. Top quartile in the Health Care sector.
Declined from 22.0% to 13.1% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -16.9pp
- 5-Year Change
- -16.9pp
- 10-Year Change
- -
Sector benchmark
Top 24% in Health CareTop 24% of 145This company 13.1% Sector average -792.7%
▼
+101.7% above sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's profit margin has declined for 4 consecutive years.
- In FY2025, profit margin decreased 37.4% year-over-year.
- Currently 805.8pp above the Health Care sector average.
- Peak profit margin was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 13.1% | -37.4% |
| FY2024 | 20.9% | -4.9% |
| FY2023 | 22.0% | -26.6% |
| FY2022 | 30.0% | -2.5% |
| FY2021 | 30.7% | +2.4% |
| FY2020 | 30.0% | -63.0% |
| FY2019 | 81.1% | +710.3% |
| FY2018 | 10.0% | -87.7% |
| FY2017 | 81.1% | +168.6% |
| FY2016 | -118.2% | -827.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026